Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 4Recruiting 4Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Cholangiocarcinoma 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × futibatinib × Clear all
NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05727176 2026-05-28

FOENIX-CCA4

Taiho Oncology, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03767075 2024-04-25

BoB

Vall d'Hebron Institute of Oncology

Phase 2 Recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡